Sun 2007.

Study characteristics
Methods	Randomisation: randomised, digital table Blinding: double‐blind, participant, investigator Duration: 10 weeks Country: no details
Participants	Diagnosis: schizophrenia (CCMD‐3) Age: 19‐48 years Sex: male and female Setting: no details Excluded: nervous system disorders and other mental illnesses; obesity disorders, history of diabetes, hypertension, heart disease; drug or alcohol dependence
Interventions	Ranitidine (300 mg/d) + olanzapine; N = 33 Placebo + olanzapine; N = 32
Outcomes	Able to use: Primary outcomes Weight measures Body weight BMI Waist circumference Waist to hip ratio Mental state PANSS
Notes	This study was translated from Chinese using an app
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation using digital table method
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not indicated
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind (participant, investigator)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome unlikely to be biased by blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Loss to follow‐up not indicated
Selective reporting (reporting bias)	Low risk	Study protocol unavailable, but all metabolic measures indicated in methods section were reported on
Other bias	Low risk	No obvious bias